Helicobacter pylori DNA and DNA-processing enzymes (H. pylori DNA/DPE)

Helicobacter pylori DNA and its associated DNA-processing enzymes constitute a vital set of targets for the eradication of chronic gastric infections. This target group includes the bacterial genome itself and essential enzymes such as DNA gyrase, which are responsible for maintaining DNA topology, facilitating replication, and enabling transcription (Source: PMID: 11517071). In H. pylori, DNA gyrase is the primary target for fluoroquinolones, which induce lethal double-stranded breaks by trapping the enzyme-DNA complex. Conversely, nitroimidazoles like metronidazole target the DNA molecule directly; once activated in the anaerobic-like environment of the bacterium, they generate toxic intermediates that destabilize the helical structure (Source: PMID: 15650219). These processes are fundamental to the survival of H. pylori within the acidic niche of the human stomach. Effective inhibition of these targets is a cornerstone of multi-drug regimens used to prevent serious complications such as peptic ulcers and gastric cancer (Source: Mayo Clinic). However, the clinical utility of targeting these molecules is increasingly threatened by the emergence of specific genetic mutations that confer high-level drug resistance.

Other names

H. pylori DNA gyraseH. pylori DNA topoisomeraseH. pylori genomic DNAH. pylori DNA polymerase

Fluoroquinolones like levofloxacin inhibit DNA gyrase (topoisomerase II) and topoisomerase IV, preventing the ligation of cleaved DNA strands and halting replication (Source: StatPearls, PMID: 30020642). Nitroimidazoles like metronidazole act as prodrugs that are reductively activated by bacterial ferredoxin, creating reactive radicals that cause direct oxidative damage and strand breakage of the bacterial DNA (Source: PubChem CID 4173).